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Background 43 
Large-scale evidence from randomised placebo-controlled trials has shown that statin therapy 44 
reduces the incidence of major vascular events (i.e., coronary deaths or myocardial infarctions, 45 
ischaemic strokes and coronary revascularisation procedures) by about one quarter for each 1 46 
mmol/L LDL-cholesterol reduction during each year (after the first) that it continues to be taken.1 47 
The proportional reductions in risk were similar in secondary and primary prevention, and were 48 
somewhat greater among lower-risk individuals (although the absolute benefits were smaller). 49 
These findings have resulted in guidelines recommending that statin therapy be considered for all 50 
patients who have experienced an atherosclerotic event and, in primary prevention, for individuals 51 
who have a 10 year risk of having a cardiovascular event (defined as coronary death, myocardial 52 
infarction, angina stroke, or transient ischaemic attack) of at least 10%, as well as for those with 53 
high LDL-cholesterol levels or relevant co-morbidity (such as diabetes).2,3 54 
 55 
Concerns have been expressed about the expansion in statin use produced by lowering risk 56 
thresholds for offering statin therapy to patients.4,5 In making the argument against so-called 57 
“over-medicalization” of the population, it has been claimed that statin therapy causes increased 58 
rates of adverse events and symptomatic side-effects (chiefly muscle pain and weakness) that 59 
prevent as many as one fifth of patients from continuing to take statin therapy long-term.5,6  These 60 
claims have usually derived from observational studies using health-care databases which, since 61 
they are neither randomised nor blinded, are subject to potential biases in the assessment of 62 
causation.7 By contrast, in double-blind randomised trials of statin therapy, the reported rates of 63 
different types of adverse event have generally been similar among patients receiving statin or 64 
placebo treatment (except for reductions in atherosclerotic events), with no differences between 65 
the groups in the rates of treatment cessation in association with adverse events7,8,9,10.  66 
 67 
It has been suggested that the lack of an excess of AEs in randomised controlled trials of statin 68 
therapy might be due to their ascertainment not being sufficiently specific or sensitive.5,11  The 69 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)12 provides a unique opportunity to assess the 70 
impact of blinded and un-blinded ascertainment of AEs identified using the same approach during 71 
blinded randomised statin therapy in the Lipid-lowering arm (LLA) of the trial13 (i.e., the “blinded 72 
randomised” phase) and during the subsequent follow-up period when a proportion of patients 73 
were taking open-label statin (the “non-blinded non-randomised” phase).14 Four AEs of interest 74 
(AEOI) were pre-specified due to the public health impact of widespread claims about muscle-75 
related side-effects and the addition to the drug label of erectile dysfunction, sleep disturbance 76 
and cognitive impairment as possible side-effects based on reviews by MHRA and FDA.15,16 77 
 78 
Methods  79 
Details of the ASCOT protocol, including study design, organization, clinical measurements, power 80 
calculations, recruitment rates, and baseline characteristics have been published12 and further 81 
information is available on the trial website (www.ascotstudy.org). ASCOT was an independent, 82 
investigator-led, multicentre study. Men and women aged between 40 and 79 years were eligible 83 
if they had > 3 risk factors for CV disease but had no history of myocardial infarction and were not 84 
being treated for angina. They were randomly assigned in an open-label comparison between two 85 
antihypertensive treatment regimens and, by using a 2 X 2 factorial design, between atorvastatin 86 
10 mg daily versus placebo in the blinded LLA comparison.  87 
 88 
The study conformed to good clinical practice guidelines and the Declaration of Helsinki. The 89 
protocol and all subsequent amendments were reviewed and ratified by central and regional 90 
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ethics review boards in the UK and by national ethics and statutory bodies in Ireland and the 91 
Nordic countries (Sweden, Denmark, Iceland, Norway, and Finland). 92 
 93 
ASCOT-LLA and LLA-extension phases 94 
Patients included in the ASCOT blood pressure-lowering comparison (BPLA) were also eligible for 95 
inclusion in the LLA comparison if they had a total cholesterol concentration of 6·5 mmol/L or less 96 
and were not taking a statin or a fibrate. There was no formal run in period to test for tolerance to 97 
statins and few, if any, patients had any prior exposure to statin treatment. 10,305 patients were 98 
randomised in the LLA between 1998 and 2000, but 65 were withdrawn soon after randomisation 99 
due to concerns about source documentation validation. For the remaining 10,240 patients, the 100 
randomly assigned atorvastatin or placebo  was stopped for efficacy (at the recommendation of 101 
the Data Safety and Monitoring Board)  in 2002, after a median of 3·3 years of active follow-up,  102 
(the period hitherto referred as the “blinded randomised phase” of the ASCOT-LLA).13 The patients 103 
were then told whether they had been assigned atorvastatin or placebo, but they  continued to be 104 
actively followed in the same way until 2004, for a median of 2·2 years, while the ASCOT-BPLA 105 
comparison continued.14 During that period they were offered open-label atorvastatin (the “non-106 
blinded non-randomised phase”), approximately two thirds of the patients opted to commence or 107 
continue open-label statin therapy (“users”) while one third did not (“non-users”); see figure 1.  108 
  109 
Adverse Event recording, classification and adjudication 110 
Following randomisation, study participants were scheduled to be seen at six weeks, three months 111 
and, thereafter, at six monthly intervals during both the blinded randomised and the non-blinded 112 
non-randomised phase of the ASCOT-LLA (until the ASCOT-BPLA completed ). At each study visit, 113 
all AEs reported by participants were recorded by the study team in the case report form (CRF). 114 
Specific questions relating to any putative AEs were not asked at these visits. During total follow-115 
up for a median of 5·5 years among 10,240 randomised patients in the LLA, there were 60,612 116 
distinct AEs (i.e., after removing multiple reports from the database of the same AE occurrence).  117 
 118 
Reports of AEs by study participants were initially recorded verbatim and subsequently classified 119 
using the Medical Dictionary for Regulatory Activities (MedDRA)17 into 26 separate system organ 120 
classification (SOC) groups, 2,288 unique preferred terms, and 5,109 separate lower level terms. 121 
For the present report, two physicians (AW and DT) adjudicated the four AEs of interest (AEOI): 122 
muscle-related, erectile dysfunction, sleep disturbance and cognitive impairment. Each of the 123 
adjudicators reviewed (blind to baseline characteristics, randomised treatment, non-study statin 124 
use, and trial phase) all reported AEs for the presence of any of the four AEOIs and, based on the 125 
description in the CRF, classified their degree of certainty (definite, probable or possible) according 126 
to pre-specified definitions. Further details are given in supplementary table 4. Any disagreements 127 
between the two adjudicators were independently resolved by a third physician (AG), who was 128 
similarly blinded.  129 
 130 
Statistical analysis 131 
Cox proportional hazard models were used to compare time to first AE in the blinded  phase 132 
between patients randomly assigned atorvastatin versus those randomly assigned placebo, and in 133 
the non-blinded non-randomised phase between patients who were exposed to statin therapy 134 
during that phase (“users”) versus those who were not exposed (“non-users”). Patients were 135 
considered to be non-users in the non-blinded non-randomised phase until statin treatment was 136 
given for at least two consecutive days (i.e., events occurring beforehand were included in the 137 
non-user group, whereas events occurring after statin use had started were included in the “user” 138 
group even if the treatment had been stopped). Consequently, time-updated Cox-models were 139 
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used for the comparisons of time to first AE between statin users and non-users. Hazard ratios 140 
(HRs) and 95% confidence intervals (95% CIs) were calculated for the pre-specified primary 141 
outcome for each AEOI of the combination of definite and probable events,  with subsidiary 142 
sensitivity analyses of definite AEOIs only and of all AEOIs (i.e., including those considered to be 143 
only possible AEOIs). Primary analyses did not involve adjustment for baseline characteristics at 144 
the time of randomisation, but subsidiary analyses were conducted of the non-blinded 145 
comparisons with adjustment for baseline characteristics.  All of the reported AEs not classified as 146 
one of the four AEOIs were also analysed grouped by SOC. Incident rates where applicable were 147 
reported as percentage per annum (% pa). 148 
 149 
Results 150 
The blinded randomised phase of the LLA was conducted from 1998 to 2002, and the non-blinded 151 
non-randomised phase from 2002 to 2004. Of the 10,240 eligible randomised patients, 60 (33 152 
atorvastatin; 27 placebo) were excluded from these analyses as they were missing end dates for 153 
the blinded phase. A further 281 patients (129 atorvastatin; 152 placebo) had either died or been 154 
censored (i.e., those who stopped routine follow-up prior to the end of LLA), and were therefore 155 
only included in the blinded analyses. Among 9,899 patients in the non-blinded non-randomised 156 
phase, 6,409 (64·7%) were users of statin therapy (most commonly atorvastatin 10mg) at some 157 
time during that period, with 52% using it immediately after the end of the blinded randomised 158 
phase.   159 
 160 
Table 1 describes the baseline characteristics at the time of randomisation among patients who 161 
were randomly assigned atorvastatin or placebo in the blinded randomised phase, and among  162 
those who were users and non-users of statin therapy in the non-blinded non-randomised phase. 163 
The patients were predominantly male, with an average age of 63 years at baseline.  No material 164 
differences in baseline characteristics were observed between the randomised treatment groups. 165 
However, in the non-randomised phase, users of statin therapy were less likely than non-users to 166 
be women or to have been smokers, and more likely to have had diabetes at baseline. Patients 167 
who had reported AEOIs during the blinded phase were slightly less likely to use a statin during the 168 
open phase. (supplementary table 1). 169 
 170 
Adverse events in the blinded randomised phase 171 
Adverse events of interests (AEOI): During the blinded randomised phase of ASCOT-LLA, the rate 172 
of reporting of definite or probable muscle-related AEOIs was similar among patients randomly 173 
assigned atorvastatin or placebo (298 [2·03%pa] vs 283 [2·00%pa]; HR 1·03 [95%CI 0·88-1·21]: 174 
table 2). Compared with placebo, the rate of reports of erectile dysfunction was slightly, but non-175 
significantly, lower among the patients assigned atorvastatin (272 [1·86%pa] vs 302 [2·14%pa]; HR 176 
0·88 [0·75-1·04]). Patients assigned to receive atorvastatin reported sleep disturbance significantly 177 
less often than did those assigned placebo (149 [1·00%pa] vs 210 [1·46%pa]; HR 0·69 [0·56-0·85]; 178 
p=0.0005 before any adjustment for multiple comparisons). However, too few cases of cognitive 179 
impairment were reported (31 [0·20%pa] vs 32 [0·22%pa]) for a statistically reliable analysis (HR 180 
0·94 [0·57-1·54]). There were similar findings in sensitivity analyses based on definite AEOIs alone 181 
or when the larger number of possible AEOIs were included (figure 2). 182 
 183 
Other adverse events: Compared with patients assigned placebo, the rates of reports of all other 184 
AEs grouped by SOC categories were similar among patients assigned atorvastatin (table 3), with 185 
the exception of a small excess of AEs attributed to renal and urinary disorders (481 [1·87%pa] vs 186 
392 [1·51%pa]; HR 1·23 [1·08 to 1·41]; p=0.0021: table 3). Subdivision of that SOC, indicates the 187 
excess was chiefly due to reports of nocturia and urinary frequency (supplementary table 2).  188 
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 189 
There were no differences between the treatment groups in the rates of serious AEs (except for 190 
reductions in atherosclerotic events)13 or treatment cessation in association with adverse events 191 
(supplementary table 3; www.ascotstudy.org). In particular, there was no excess of serious AEs 192 
that had been attributed to musculoskeletal or connective tissue disorders. However, one case of 193 
non-fatal rhabdomyolysis was reported in a man receiving atorvastatin who had had a very high 194 
alcohol intake and a recent febrile illness. 195 
 196 
Adverse events in the non-blinded non-randomised phase 197 
Adverse events of interest: During the non-blinded non-randomised extension phase of ASCOT-198 
LLA, overall reporting rates for AEOIs were lower than in the blinded phase of the trial.  However, 199 
muscle-related AEOIs were reported at a higher rate by statin users than by those who were not 200 
(161 [1·26%pa] vs 124 [0·90%pa]; HR 1·41 [1·10-1·79]; p=0.0059: table 2). The proportional excess 201 
was similar among patients who had been assigned atorvastatin (HR 1·49 [1·05-2.11]) or placebo 202 
(HR 1·33 [0·96-1·84]) during the blinded randomised phase (interaction p=0·63). 203 
 204 
There were no significant differences between statin users and non-users in the reported rates of 205 
erectile dysfunction (88 [0·68%pa] vs 99 [0·80%pa]; HR 0·89 [0·66 to 1·20]), sleep disturbance (72 206 
[0·56%pa] vs 82 [0·66%pa]; HR 0·87 [0·63 to 1·20]) or cognitive impairment (22 [0·17%pa] vs 36 207 
[0·29%pa]; HR 0·59 [0·34-1·02]: table 2). 208 
 209 
There were similar findings in the sensitivity analyses based on definite AEOIs alone or when the 210 
larger number of possible AEOIs were included (figure 2). A subsidiary analysis of the non-blinded 211 
comparisons adjusted for baseline characteristics (age, sex, race, smoking, diabetes, left 212 
ventricular hypertrophy, total cholesterol and systolic blood pressure), had minimal effect on the 213 
HRs. For muscle-related AEs, the adjusted HR was 1.43 [1.12-1.83]  214 
  215 
Other adverse events: The rates of reports of all other AEs grouped by SOC categories, were 216 
similar among the patients who were using and not using statin therapy (table 4), with the 217 
exception of an excess among statin users of AEs attributed to musculoskeletal and connective 218 
tissue disorders (992 [8·69%pa] vs 831 [7·45%pa]; HR 1·17 [1·06-1·29]; p=0·0012). There were no 219 
differences in the rates of serious AEs between users and non-users (supplementary table 5). 220 
 221 
Discussion 222 
The ASCOT-LLA trial provides a unique opportunity to compare the rate of reporting of AEs using  223 
an identical follow-up procedure and AE ascertainment process in the same individuals during 224 
blinded randomised  and non-blinded non-randomised statin therapy.   There was no excess of 225 
reports of muscle-related AEs among patients assigned statin therapy during the blinded 226 
randomised phase, but there was a significant excess when patients knew that they were taking a 227 
statin during the subsequent non-blinded phase. This observation is consistent with a “nocebo” 228 
effect, whereby subjective AEs (e.g., symptoms reported by patients) may be more likely to be 229 
attributed to a treatment thought to cause some particular side-effect.18 230 
 231 
Statin therapy has been shown to cause myopathy (i.e., muscle pain or weakness combined with 232 
large increases in blood concentrations of creatine kinase) in about 1 per 10,000 patients per year 233 
of treatment.19 However, in  double-blind randomised trials of statin therapy, muscle-related 234 
symptoms have generally been reported with similar frequency by patients  assigned statin or 235 
placebo treatment.  236 
 237 
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Although muscle-related problems were not sought systematically in all such  trials, sufficiently 238 
large numbers of cases have been reported to detect or rule out small excesses.7 For example, a 239 
meta-analysis of 26 blinded randomised trials found little difference in the  rates of muscle 240 
problems reported during an average treatment duration of three years: 7,544 cases (12·7%) 241 
among 59,237 participants assigned statin versus 6,735 (12·4%) among 54,458 assigned placebo.20  242 
Combination of the reported  results in the large placebo-controlled trials eligible for the 243 
Cholesterol Treatment Trialists’ Collaborative meta-analyses1 yielded similar results: 5,162 (11·7%) 244 
cases allocated statin therapy versus 5,015 (11·4%) allocated placebo during an average of five 245 
years of treatment (p=0·10).7, The numbers of cases of muscle-related problems that led to the 246 
randomised study treatment being stopped were also found to be similar. Consequently, it has 247 
been estimated that any excess of symptomatic muscle pain or other muscle-related problems 248 
that is actually caused by statin therapy is likely to be no more than about 0·1-0·2% per year of 249 
treatment.7  250 
 251 
Despite these results from blinded randomised trials, the increasingly widespread use of statins 252 
has been associated with increasingly common reports of so-called “statin intolerance”6,21 chiefly 253 
attributed to muscle pain or weakness.6   Indeed, based on non-randomised observational studies 254 
of statin use in routine care, it has been claimed that as many as one-fifth of patients are not able 255 
to tolerate statin therapy.5,22  However, patients who are taking a treatment as part of their 256 
routine care know they are doing so (as do their doctors) and they may also be specifically told 257 
that the treatment has particular side-effects (e.g. patients given statin therapy are typically 258 
advised that serious muscle problems can arise rarely).  This inherent lack of blinding in 259 
observational studies may introduce substantial ascertainment bias, particularly for the 260 
assessment of the effects of a treatment on substantive outcomes.7,18  The contrast between the 261 
similarity of the rates of muscle-related symptoms reported during the blinded randomised phase 262 
of ASCOT-LLA and the excess associated with statin use during the non-blinded non-randomised 263 
phase illustrates this problem.  Moreover, the present analyses may well under-estimate the 264 
impact of the nocebo effect because ASCOT-LLA was conducted during 1998-2004, before claims 265 
that statin therapy causes high rates of side-effects had become as common as they are now. 266 
 267 
 268 
We selected three other categories of AE for scrutiny because the regulatory authorities  had  269 
added them to the drug label as possible statin side-effects16,17 based largely on  associations in 270 
observational studies (and despite a general lack of support for such associations in randomised 271 
trials).7 Unexpectedly, and by contrast with the regulatory concerns, the rate of reports of sleep 272 
disturbances was reduced by about one third among patients assigned  atorvastatin during the 273 
blinded randomised phase of ASCOT-LLA ( but not with statin use  during the non-blinded non-274 
randomised phase).. A beneficial effect of statin use on sleep disturbance has not previously been 275 
reported,7,23 and it may be that this difference was due to chance (although it  is conventionally 276 
significant after adjustment for multiple comparisons).  There were also fewer reports of erectile 277 
dysfunction in ASCOT-LLA among patients assigned atorvastatin during the blinded randomised 278 
phase, but that difference did not achieve statistical significance (irrespective of whether the 279 
analyses were restricted to definite cases or included all reported cases). 280 
 281 
There were too few reported cases of cognitive impairment during ASCOT-LLA to assess the effects 282 
of statin therapy reliably. However, specific assessment of this outcome among large numbers of 283 
older people in the PROSPER and HPS randomised placebo-controlled trials,24,25 as well as in trials 284 
among people who already had pre-existing cognitive impairment, provides good evidence that 285 
statin therapy has little effect on memory loss or other measurers of cognitive function.7,13 Most 286 
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recently, it has been reported that there was no effect of statin therapy on cognitive decline or 287 
memory loss among the 12,000 patients in the randomised blinded HOPE-3 trial.26 In exploratory 288 
analyses of all other AE reports grouped according to SOC, we did not find significant differences 289 
during the blinded randomised phase, with the exception of a small excess of reports of renal and 290 
urinary disorders in the atorvastatin group which appeared to be related to increased frequency of 291 
micturition and nocturia. As far as we are aware, such an excess has not previously been reported. 292 
Given the small number of events on which it is based, the large number of separate comparisons 293 
made, and their exploratory nature, it may well be that this apparent difference is due to chance.  294 
 295 
Our findings were not materially altered when the analyses were based on reports of only those 296 
AEs that were considered to be definite, or when the larger numbers of probable and possible AEs 297 
were included (which tend to increase statistical power to detect an effect of a particular size, but 298 
might decrease sensitivity due to dilution of the treatment effect by including events that are not 299 
actually the AE of interest). 300 
  301 
The ASCOT trial was conducted in a hypertensive population in the UK, Ireland and the Nordic 302 
countries among patients who were predominately aged over 60 years, male and of European 303 
ancestry. It seems likely that the findings would  be generalisable to younger and older patients, 304 
(particularly given the results from other blinded randomised trials in such individuals), but it may 305 
not be generalisable to people from other ethnic groups.   Atorvastatin at a daily dose of 10mg 306 
was studied specifically only in the blinded phase of the trial, but most of the patients in the open 307 
phase who took a statin used the same dose of atorvastatin, with only a few using simvastatin. 308 
Atorvastatin  10mg daily would now be considered a relatively low dose, but randomised trials of 309 
higher doses have also not found differences in muscle-related  AEs, other than the very small 310 
excess of myopathy (as described above).  311 
 312 
The widespread media coverage that has been engendered by claims that statin therapy causes 313 
side effects in up to one fifth of patients,5,27 and the failure to correct such misleading claims 314 
rapidly and properly has led to high risk patients with established cardiovascular disease stopping 315 
their statin therapy.28,29 It has been estimated that such reductions in statin use may result in 316 
thousands of fatal and disabling heart attacks and strokes occurring, that would otherwise have 317 
been avoided. Seldom in the history of modern therapeutics have the substantial proven benefits 318 
of a treatment been compromised to such an extent by serious misrepresentations of the 319 
evidence about its safety. We hope that the demonstration in ASCOT-LLA of not only the lack of 320 
adverse effects of statin therapy on muscle-related and other AEs, but also the impact of 321 
ascertainment bias in non-blinding studies (which have been the basis of many of the misleading 322 
claims) will help to counter the adverse effect on public health of exaggerated claims about statin 323 
side-effects. 324 
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Table 1.   Baseline characteristics among those allocated to atorvastatin and placebo in the blinded phase of the 
LLA of the ASCOT trial, and among users and non-users in the non-blinded non-randomized phase of LLA-
extension 
 
   Blinded randomized (LLA) phase Non-blinded non-randomized (LLA-extension) phase* 
  Placebo Atorvastatin Non-user User 
(n = 5079) (n = 5101) (n = 3490) (n = 6409) 
Patients characteristics         
Woman 949 (18.7%) 955 (18.7%) 760 (21.8%) 1097 (17.1%) 
Age (years)         
    ≤ 60.0 1821 (35.9%) 1842 (36.1%) 1204 (34.5%) 2405 (37.5%) 
    > 60.0 3258 (64.2%) 3259 (63.9%) 2286 (65.5%) 4004 (62.5%) 
White Ethnicity 4805 (94.6%) 4822 (94.5%) 3367 (96.5%) 5996 (93.6%) 
Current smoker 1644 (32.4%) 1697 (33.3%) 1250 (35.8%) 1987 (31.0%) 
Alcohol consumption per 
week 
        
    ≤ 14.0 units 4149 (81.7%) 4170 (81.8%) 2916 (83.6%) 5175 (80.8%) 
    > 14.0 units 929 (18.3%) 929 (18.2%) 574 (16.4%) 1231 (19.2%) 
Systolic blood pressure, 
mm Hg 
164.2 (18.0) 164.2 (17.7) 166.0 (18.2) 163.2 (17.6) 
Diastolic blood pressure, 
mm Hg 
95.0 (10.3) 94.9 (10.3) 95.8 (10.6) 94.6 (10.0) 
Heart rate, beats/min 71.8 (12.6) 71.2 (12.7) 71.6 (12.4) 71.4 (12.8) 
BMI, kg/m2 28.7 (4.6) 28.6 (4.7) 28.5 (4.7) 28.8 (4.6) 
Total cholesterol, mmol/L 5.5 (0.8) 5.5 (0.8) 5.4 (0.8) 5.5 (0.8) 
LDL- cholesterol, mmol/L 3.4 (0.7) 3.4 (0.7) 3.4 (0.7) 3.5 (0.7) 
HDL- cholesterol, mmol/L 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 
Triglycerides, mmol/L 1.6 (0.9) 1.7 (0.9) 1.6 (0.8) 1.7 (0.9) 
Glucose, mmol/L 6.2 (2.1) 6.2 (2.1) 6.1 (2.0) 6.2 (2.1) 
Creatinine, mmol/L 98.9 (16.4) 99.1 (16.6) 98.6 (17.1) 99.1 (15.9) 
Medical History         
Previous stroke or TIA 524 (10.3%) 493 (9.7%) 350 (10.0%) 630 (9.8%) 
Diabetes (T2DM) 1267 (25.0%) 1254 (24.6%) 792 (22.7%) 1660 (25.9%) 
LVH (on ECG or ECHO) 721 (14.2%) 735 (14.4%) 478 (13.6%) 927 (14.5%) 
ECG abnormalities other 
than LVH 
721 (14.2%) 731 (14.3%) 483 (13.8%) 908 (14.2%) 
Peripheral vascular disease 251 (4.9%) 259 (5.1%) 166 (4.8%) 318 (5.0%) 
Other relevant 
cardiovascular disease 
204 (4.0%) 184 (3.6%) 135 (3.9%) 234 (3.7%) 
Mean (SD) number of risk 
factors 
3.7 (0.9) 3.7 (0.9) 3.6 (0.8) 3.7 (0.9) 
Previous antihypertensive 
treatments 
        
    None 977 (19.2%) 1000 (19.6%) 769 (22.0%) 1163 (18.2%) 
       1 2252 (44.3%) 2286 (44.8%) 1571 (45.0%) 2842 (44.3%) 
    > 1 1850 (36.4%) 1815 (35.6%) 1150 (33.0%) 2404 (37.5%) 
Previous lipid-lowering 
treatment 
44 (0.9%) 34 (0.7%) 31 (0.9%) 46 (0.7%) 
Aspirin use 881 (17.4%) 900 (17.6%) 527 (15.1%) 1188 (18.5%) 
 
Data not shown as n (%) are mean (SD). BMI = body mass index.  TIA = transient ischaemic attack.  LVH = left-
ventricular hypertrophy. ECG = echocardiogram. ECHO = echocardiogram. 
 
*Note. 281 patients were included in the analysis of the blind period only, and hence are not included in this phase. 
 
 
  
Table 2.  Risk (hazards ratio) for the adverse events of interest in the blinded randomised and un-blinded non-
randomised phase of the ASCOT-LLA 
 
ASCOT-LLA phase Blinded Randomized Phase (3.3 years) 
Open Non-Randomized Phase (2.2 
years) 
Adverse Event of Interest* 
Placebo 
(n = 5,079) 
Atorvastatin 
(n = 5,101) 
Non-user 
(n = 3,490) 
Statin-user 
(n = 6,409) 
Muscle related* 
Nos. of patients 283  298  124  161  
Rate (% pa) 2.00 2.03 1.00 1.26 
HR (95% CI) 1.03 (0.88, 1.21), p=0.7229 1.41 (1.10, 1.79), p=0.0059 
Erectile dysfunction* 
Nos. of patients 302  272  99  88  
Rate (% pa) 2.14 1.86 0.80 0.68 
HR (95% CI) 0.88 (0.75, 1.04) , p=0.1260 0.89 (0.66, 1.20), p=0.4447 
Sleep disturbance* 
Nos. of patients 210  149  82  72  
Rate (% pa) 1.46 1.00 0.66 0.56 
HR (95% CI) 0.69 (0.56, 0.85), p=0.0005 0.87 (0.63, 1.20), p=0.3992 
Cognitive impairment* 
Nos. of patients 32  31  36  22  
Rate (% pa) 0.22 0.20 0.29 0.17 
HR (95% CI) 0.94 (0.57, 1.54), p=0.8098 0.59 (0.34, 1.02), p=0.0576 
 
* First event only in each phase, definite and probable AEs; number of patients with at least one event reported. 
  
Table 3.   Incident rates of all adverse events, stratified by system organ classification, among those allocated to 
either statin or placebo in the blinded randomized phase of the ASCOT-LLA (median follow-up, 3.3 years) 
 
 
System Organ Class 
Rate [% per annum] 
Hazard ratio 
(95% CI) 
P-value 
Placebo Atorvastatin 
Blood and lymphatic system disorders 0.33 0.25 0.78 (0.57, 1.07) 0.1179 
Cardiac disorders 1.89 1.92 1.02 (0.90, 1.15) 0.7801 
Congenital, familial and genetic disorders 0.05 0.05 0.99 (0.47, 2.08) 0.9840 
Ear and labyrinth disorders 1.38 1.30 0.95 (0.82, 1.10) 0.4569 
Endocrine disorders 0.09 0.09 1.03 (0.59, 1.81) 0.9065 
Eye disorders 1.37 1.36 0.99 (0.86, 1.15) 0.9299 
Gastrointestinal disorders 5.70 5.72 1.01 (0.93, 1.09) 0.8668 
General disorders and administration site conditions 4.81 4.91 1.02 (0.94, 1.11) 0.6104 
Hepatobiliary disorders 0.17 0.15 0.88 (0.58, 1.35) 0.5675 
Immune system disorders 0.13 0.13 0.97 (0.61, 1.53) 0.8830 
Infections and infestations 7.72 7.53 0.98 (0.92, 1.05) 0.6060 
Injury, poisoning and procedural complications 1.90 1.80 0.95 (0.84, 1.08) 0.4319 
Investigations 1.07 1.00 0.94 (0.79, 1.11) 0.4322 
Metabolism and nutrition disorders 0.96 0.85 0.89 (0.75, 1.07) 0.2054 
Musculoskeletal and connective tissue disorders 6.91 7.19 1.04 (0.96, 1.11) 0.3270 
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps) 
1.01 0.98 0.97 (0.82, 1.15) 0.7287 
Nervous system disorders 5.97 6.18 1.03 (0.96, 1.12) 0.3950 
Psychiatric disorders 0.12 0.07 0.59 (0.33, 1.04) 0.0678 
Renal and urinary disorders 1.51 1.87 1.23 (1.08, 1.41) 0.0021 
Reproductive system and breast disorders 0.83 0.82 1.00 (0.83, 1.20) 0.9776 
Respiratory, thoracic and mediastinal disorders 4.83 4.76 0.98 (0.91, 1.07) 0.7225 
Skin and subcutaneous tissue disorders 2.70 2.53 0.94 (0.84, 1.05) 0.2752 
Social circumstances 0.02 0.01 0.66 (0.19, 2.35) 0.5232 
Surgical and medical procedures 0.52 0.53 1.03 (0.82, 1.30) 0.8018 
Vascular disorders 1.96 1.73 0.89 (0.78, 1.01) 0.0699 
Uncoded 0.18 0.16 0.87 (0.58, 1.31) 0.5091 
 
Rate in percentage per annum (equivalent to rate per 100 patient years); hazard ratio from Cox PH model 
 
 
  
Table 4.  Incident rates of all adverse events, stratified by system organ classification, among statin-users and 
non-users in the non-blinded non-randomized phase of the LLA-extension (median follow-up, 2.2 years) 
 
System Organ Class 
Rate (% per annum) 
Hazard Ratio  
(95% CI) 
P-value 
Non-User Statin-User 
Blood and lymphatic system disorders 0.64 0.88 1.40 (1.04, 1.88) 0.0278 
Cardiac disorders 2.46 2.41 0.96 (0.82, 1.14) 0.6639 
Congenital, familial and genetic disorders 0.14 0.17 0.97 (0.51, 1.83) 0.9156 
Ear and labyrinth disorders 1.35 1.42 1.04 (0.84, 1.30) 0.7062 
Endocrine disorders 0.18 0.17 0.92 (0.50, 1.68) 0.7828 
Eye disorders 1.88 1.92 1.00 (0.83, 1.20) 0.9887 
Gastrointestinal disorders 6.32 6.19 1.01 (0.90, 1.12) 0.9076 
General disorders and administration site conditions 3.91 4.05 1.10 (0.97, 1.26) 0.1419 
Hepatobiliary disorders 0.36 0.25 0.70 (0.44, 1.12) 0.1378 
Immune system disorders 0.22 0.15 0.63 (0.35, 1.13) 0.1223 
Infections and infestations 9.62 9.42 0.96 (0.88, 1.05) 0.3663 
Injury, poisoning and procedural complications 2.58 2.76 1.07 (0.91, 1.25) 0.4037 
Investigations 1.49 1.51 0.98 (0.79, 1.21) 0.8419 
Metabolism and nutrition disorders 1.64 1.30 0.81 (0.65, 1.00) 0.0494 
Musculoskeletal and connective tissue disorders 7.45 8.69 1.17 (1.06, 1.29) 0.0012 
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps) 
1.93 1.95 1.02 (0.85, 1.23) 0.8339 
Nervous system disorders 5.23 4.79 0.94 (0.84, 1.06) 0.3197 
Psychiatric disorders 0.14 0.12 0.84 (0.41, 1.72) 0.6416 
Renal and urinary disorders 2.20 2.41 1.11 (0.94, 1.31) 0.2330 
Reproductive system and breast disorders 1.45 1.41 0.92 (0.74, 1.13) 0.4169 
Respiratory, thoracic and mediastinal disorders 4.50 4.30 0.98 (0.87, 1.12) 0.8046 
Skin and subcutaneous tissue disorders 2.98 2.94 0.98 (0.84, 1.14) 0.7971 
Social circumstances 0.02 0.02 0.51 (0.08, 3.09) 0.4638 
Surgical and medical procedures 0.75 0.92 1.20 (0.91, 1.60) 0.1965 
Vascular disorders 1.73 1.51 0.89 (0.73, 1.09) 0.2638 
Uncoded 0.18 0.31 1.80 (1.05, 3.08) 0.0332 
 
Incident rates in percentage per annum (equivalent to incident rate per 100 patient years); hazard ratio from time-
updated Cox PH model.  
 
Figure 1:  Patient flow in the ASCOT-LLA and LLA-extension  
 
 
* Censored: due to lost follow-up prior to completion of LLA  
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Supplementary Table 1 
 
Table showing percentage of “users” in the open period stratified by whether or not they experienced each of the 
4 AEOI’s (definite/probable) during the blind period 
 
 
AEOI Blind Period 
(definite/probable) 
User in Open 
period 
P-value 
User in Open period 
Interaction p-
value 
Placebo Statin 
Muscle related      
No 65.0%  61.9% 68.1%  
Yes 60.5% 0.0299 59.9% 61.1% 0.2087 
      
Cognitive impairment     
No 64.8%  61.8% 67.7%  
Yes 62.9% 0.7609 64.5% 61.3% 0.4511 
      
Insomnia      
No 64.9%  61.9% 67.8%  
Yes 61.4% 0.1765 59.0% 64.6% 0.9354 
      
Erectile dysfunction     
No 64.9%  62.0% 67.7%  
Yes 62.9% 0.3311 58.6% 67.5% 0.4489 
 
  
Supplementary Table 2.   
 
Incident rate of renal and bladder complaints according to preferred terms, among those on either placebo or 
statin and categorised in the system organ classification for renal and urinary disorders in the blinded randomized 
phase of the LLA 
 
 Blinded Randomized Period of LLA 
  
Serious and non-serious events Number of patients experiencing event 
(%) 
Rate % per annum  Hazard ratio*  
Placebo Statin Placebo Statin  
 n % n % Hazard 
Ratio 
(95% CI) P-value 
Albuminuria 6 0.12 1 0.02 0.04 0.01 0.16 (0.02, 1.36) 0.094 
Anuria 2 0.04 1 0.02 0.01 0.01 - - - 
Bilateral hydronephrosis 0 0.00 1 0.02 0.00 0.01 - - - 
Bilirubinuria 0 0.00 1 0.02 0.00 0.01 - - - 
Bladder discomfort 1 0.02 1 0.02 0.01 0.01 - - - 
Bladder disorder 3 0.06 2 0.04 0.02 0.01 - - - 
Bladder obstruction 2 0.04 0 0.00 0.02 0.00 - - - 
Bladder pain 1 0.02 2 0.04 0.01 0.01 - - - 
Bladder prolapse 0 0.00 1 0.02 0.00 0.01 - - - 
Bladder spasm 0 0.00 1 0.02 0.00 0.01 - - - 
Bladder stenosis 1 0.02 1 0.02 0.01 0.01 - - - 
Calculus bladder 0 0.00 3 0.06 0.00 0.02 - - - 
Calculus ureteric 4 0.08 2 0.04 0.03 0.01 - - - 
Calculus urethral 0 0.00 1 0.02 0.00 0.01 - - - 
Calculus urinary 10 0.20 8 0.16 0.07 0.05 0.78 (0.31, 1.97) 0.594 
Chromaturia 3 0.06 1 0.02 0.02 0.01 - - - 
Costovertebral angle tenderness 1 0.02 0 0.00 0.01 0.00 - - - 
Cystocele 3 0.06 1 0.02 0.02 0.01 - - - 
Dysuria 40 0.79 34 0.67 0.29 0.32 0.88 (0.55, 1.39) 0.577 
Enuresis 1 0.02 0 0.00 0.01 0.00 - - - 
Glomerulonephritis proliferative 1 0.02 0 0.00 0.01 0.00 - - - 
Glycosuria 3 0.06 1 0.02 0.02 0.01 - - - 
Haematuria 75 1.48 98 1.92 0.53 0.68 1.27 (0.94, 1.73) 0.122 
Hydronephrosis 1 0.02 1 0.02 0.01 0.01 - - - 
Hypertonic bladder 1 0.02 2 0.04 0.01 0.01 - - - 
Incontinence 21 0.41 22 0.43 0.14 0.14 1.08 (0.59, 1.97) 0.812 
Leukocyturia 0 0.00 1 0.02 0.00 0.01 - - - 
Microalbuminuria 0 0.00 6 0.12 0.00 0.05 - - - 
Micturition disorder 10 0.20 6 0.12 0.07 0.04 0.65 (0.23, 1.82) 0.410 
Micturition urgency 17 0.33 29 0.57 0.11 0.21 1.61 (0.88, 2.94) 0.121 
Nephritis 0 0.00 1 0.02 0.00 0.01 - - - 
Nephrolithiasis 16 0.32 22 0.43 0.11 0.15 1.53 (0.78, 3.00) 0.211 
Nephropathy 1 0.02 1 0.02 0.01 0.01 - - - 
Nocturia 57 1.12 84 1.65 0.40 0.55 1.43 (1.01, 2.02) 0.041 
Oliguria 1 0.02 1 0.02 0.01 0.01 - - - 
Pollakiuria 83 1.63 116 2.27 0.59 0.79 1.47 (1.10, 1.97) 0.008 
Polyuria 15 0.30 19 0.37 0.11 0.13 1.19 (0.60, 2.35) 0.627 
Proteinuria 18 0.35 12 0.24 0.13 0.09 0.65 (0.31, 1.35) 0.251 
Pyuria 0 0.00 1 0.02 0.00 0.01 - - - 
Renal artery embolism 1 0.02 0 0.00 0.01 0.00 - - - 
Renal artery stenosis 2 0.04 2 0.04 0.01 0.01 - - - 
Renal colic 3 0.06 1 0.02 0.02 0.01 - - - 
Renal cyst 3 0.06 3 0.06 0.02 0.02 - - - 
Renal disorder 3 0.06 1 0.02 0.02 0.01 - - - 
Renal failure acute 0 0.00 1 0.02 0.00 0.01 - - - 
Renal failure chronic 0 0.00 1 0.02 0.00 0.01 - - - 
Renal impairment 3 0.06 8 0.16 0.02 0.05 2.27 (0.59, 8.79) 0.234 
Renal insufficiency 1 0.02 5 0.10 0.01 0.03 4.9 (0.57, 41.94) 0.147 
Renal pain 6 0.12 2 0.04 0.04 0.01 0.32 (0.07, 1.61) 0.168 
Residual urine 0 0.00 3 0.06 0.00 0.02 - - - 
Strangury 0 0.00 1 0.02 0.00 0.01 - - - 
Stress incontinence 2 0.04 5 0.10 0.01 0.03 2.44 (0.47, 12.60) 0.285 
Urethral disorder 1 0.02 0 0.00 0.01 0.00 - - - 
Urethral haemorrhage 0 0.00 1 0.02 0.00 0.01 - - - 
Urethral obstruction 0 0.00 1 0.02 0.00 0.01 - - - 
Urethral stricture 1 0.02 1 0.02 0.01 0.01 - - - 
Urge incontinence 3 0.06 1 0.02 0.02 0.01 - - - 
Urinary bladder polyp 1 0.02 0 0.00 0.01 0.00 - - - 
Urinary hesitation 1 0.02 0 0.00 0.01 0.00 - - - 
Urinary incontinence 22 0.43 20 0.39 0.15 0.15 0.84 (0.46, 1.55) 0.580 
Urinary retention 27 0.53 17 0.33 0.19 0.11 0.61 (0.33, 1.12) 0.112 
Urinary tract disorder 10 0.20 14 0.27 0.07 0.09 1.36 (0.61, 3.07) 0.455 
Urinary tract obstruction 0 0.00 2 0.04 0.00 0.01 - - - 
Urinary tract pain 2 0.04 2 0.04 0.01 0.01 - - - 
Urine abnormality 0 0.00 1 0.02 0.00 0.01 - - - 
Urine flow decreased 3 0.06 3 0.06 0.02 0.02 - - - 
Urine odour abnormal 1 0.02 1 0.02 0.01 0.01 - - - 
Urinoma 1 0.02 0 0.00 0.01 0.00 - - - 
 
Rate percentage per annum (% pa), which is equivalent to rate 100 patient years 
* Hazard ratios were only estimated for those with events in both arm, and with cumulative incidence  >1% 
 
 
  
Supplementary Table 3.   
 
Risk (hazard ratio) of serious adverse events, stratified by system organ classification, among those allocated to 
either statin or placebo in the blinded randomized phase of the ASCOT-LLA (median follow-up, 3.3 years). 
 
 
System Organ Class Placebo Atorva-statin Hazard 
Ratio 
(95% CI) P-value 
 Rate % pa Rate % pa   P-value 
Blood and lymphatic system disorders 0.05 0.05 0.93 (0.45, 1.92) 0.836 
Cardiac disorders 0.20 0.23 1.16 (0.81, 1.67) 0.424 
Congenital, familial and genetic disorders 0.00 0.00 0.99 (0.06, 15.88) 0.996 
Ear and labyrinth disorders 0.05 0.06 1.06 (0.52, 2.14) 0.871 
Endocrine disorders 0.01 0.01 0.99 (0.20, 4.92) 0.993 
Eye disorders 0.05 0.04 0.71 (0.32, 1.60) 0.407 
Gastrointestinal disorders 0.55 0.57 1.04 (0.83, 1.30) 0.732 
General disorders and administration site conditions 0.31 0.22 0.69 (0.50, 0.96) 0.028 
Hepatobiliary disorders 0.11 0.07 0.68 (0.39, 1.21) 0.191 
Immune system disorders 0.00 0.00 0.99 (0.06, 15.89) 0.997 
Infections and infestations 0.43 0.43 0.99 (0.77, 1.28) 0.945 
Injury, poisoning and procedural complications 0.28 0.23 0.84 (0.60, 1.16) 0.288 
Investigations 0.09 0.08 0.80 (0.45, 1.42) 0.451 
Metabolism and nutrition disorders 0.07 0.03 0.45 (0.20, 0.98) 0.045 
Musculoskeletal and connective tissue disorders 0.38 0.37 0.97 (0.74, 1.28) 0.843 
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps) 
0.42 0.37 0.87 (0.67, 1.14) 0.313 
Nervous system disorders 0.33 0.26 0.79 (0.58, 1.07) 0.126 
Psychiatric disorders 0.01 0.01 0.66 (0.11, 3.97) 0.652 
Renal and urinary disorders 0.18 0.17 0.97 (0.65, 1.45) 0.889 
Reproductive system and breast disorders 0.09 0.15 1.65 (1.01, 2.68) 0.045 
Respiratory, thoracic and mediastinal disorders 0.26 0.22 0.85 (0.61, 1.20) 0.359 
Skin and subcutaneous tissue disorders 0.04 0.02 0.45 (0.16, 1.30) 0.140 
Social circumstances 0.02 0.01 0.66 (0.19, 2.35) 0.523 
Surgical and medical procedures 0.26 0.28 1.09 (0.79, 1.51) 0.593 
Vascular disorders 0.19 0.14 0.74 (0.49, 1.13) 0.163 
Uncoded 0.02 0.01 0.50 (0.12, 1.99) 0.322 
 
Incident rate percentage (%) per annum (% pa) (which is equivalent to rate per 100 person years. 
  
Supplementary Table  4.   
 
Adjudication Definitions 
Myalgia 
 
1: Possible 
 
2: Probable 
 
3: Definite 
 
- Poorly localised complaints 
suspicious for potential 
myalgia (incl. tiredness, 
fatigue, lassitude, weakness, 
loss of power or physical 
strength) 
- Also included are areas such as 
shoulder, unilateral limb 
symptoms, descriptions 
affecting small individual 
muscles or muscle groups e.g. 
suprascapularis, or 
descriptions affecting unlikely 
areas e.g. groin. 
- Exclusions: chest pain, non 
cardiac chest pain,  
‘musculoskeletal chest pain’, 
thoracic pain, abdominal pain, 
headache, lower back pain, 
neck pain, hand and foot pain, 
claudication and claudication-
equivalent descriptions 
 
- Complaints  well-localised to a 
large, muscular area that are 
reasonably likely to represent 
pain but have not specifically 
used pain or pain-equivalent 
terms, or are present with 
bilaterality, or affect large 
continuous body regions. 
- Muscular areas include: 
bilateral limbs, bilateral 
shoulders, large continuous 
areas of torso and/or limbs. 
- Terminology includes: muscle 
fatigue, muscle tiredness, 
muscle weakness 
- Exclusions: chest pain, non 
cardiac chest pain,  
‘musculoskeletal chest pain’, 
thoracic pain, abdominal pain, 
headache, lower back pain, 
neck pain, hand and foot pain, 
claudication and claudication-
equivalent descriptions 
 
- Pain or pain-equivalent term 
described as muscular or 
referring to a specified muscle.  
If the AE  specifically 
mentions ‘myalgia’ this is 
included automatically,  but 
excludes back, neck, hands, 
feet. 
- Pain equivalent terms: ache, 
spasm, cramp, dolor, myositis 
- Examples: myalgia, muscle 
pain, muscle cramp, calf ache, 
thigh pain, polymyalgia, 
polymyalgia rheumatica, 
fibromyalgia. 
Excludions: chest pain, non 
cardiac chest pain,  
‘musculoskeletal chest pain’, 
thoracic pain, abdominal pain, 
headache, lower back pain, 
neck pain, hand and foot pain, 
claudication and claudication-
equivalent descriptions 
 
Cognitive Impairment 
 
1: Possible 2: Probable 
 
3: Definitive 
 
Symptoms or events reported that 
are concerning for potential 
cognitive decline 
e.g. delerium, confusion 
Depression and  low mood 
excluded 
 
Clear reporting of symptoms or 
behavioural patterns likely 
suggestive of cognitive 
impairment 
e.g. Memory trouble, 
forgetfulness, difficulty with tasks 
such as reading, slowness of 
thought 
Depression and  low mood 
excluded 
 
Clear medical or diagnostic 
terminology reporting confirmed 
deficits in memory, concentration, 
planning, decision making 
e.g. Memory disorder, dementia 
Depression and  low mood 
excluded 
Symptoms or events reported that 
are concerning for potential 
cognitive decline 
e.g. delerium, confusion 
 Depression and  low mood 
excluded 
 
Erectile Dysfunction 
1: Possible 
 
2: Probable 
 
3: Definitive 
 
 
Complaints of sexual disturbance 
E.g. sexual dysfunction 
 
Symptoms more clearly suggestive 
of ED 
E.g. Loss of libido 
 
Impotence, erectile dysfunction 
 
 
 
  
Supplementary Table 5.  
 
Incident rates of serious adverse events, stratified by system organ classification, among statin users and non-
users in the non-blinded non-randomized phase of the LLA-extension (median follow-up, 2.2 years) 
 
System Organ Class Non-user Statin-user Hazard 
ratio 
(95% ci) P-value 
 Rate per 100 pyr       
Blood and lymphatic system disorders 0.08 0.12 1.42 (0.63, 3.18) 0.394 
Cardiac disorders 0.67 0.50 0.77 (0.55, 1.07) 0.120 
Congenital, familial and genetic disorders 0.01 0.00 0.00 (0.00, .) 1.000 
Ear and labyrinth disorders 0.07 0.05 0.69 (0.24, 2.03) 0.503 
Endocrine disorders 0.02 0.00 0.00 (0.00, .) 1.000 
Eye disorders 0.12 0.10 0.95 (0.44, 2.04) 0.886 
Gastrointestinal disorders 1.10 0.97 0.85 (0.66, 1.09) 0.208 
General disorders and administration site 
conditions 
0.63 0.55 0.94 (0.67, 1.31) 0.701 
Hepatobiliary disorders 0.21 0.17 0.83 (0.46, 1.50) 0.545 
Immune system disorders 0.04 0.02 0.35 (0.07, 1.84) 0.213 
Infections and infestations 1.00 0.93 0.88 (0.68, 1.14) 0.345 
Injury, poisoning and procedural complications 0.65 0.63 0.94 (0.68, 1.30) 0.712 
Investigations 0.14 0.25 1.95 (1.06, 3.59) 0.033 
metabolism and nutrition disorders 0.19 0.12 0.60 (0.31, 1.17) 0.137 
Musculoskeletal and connective tissue disorders 0.52 0.51 1.01 (0.71, 1.44) 0.965 
Neoplasms benign, malignant and unspecified 
(incl cysts and polyps) 
0.90 0.83 0.90 (0.69, 1.19) 0.470 
Nervous system disorders 0.74 0.56 0.73 (0.53, 1.01) 0.055 
Psychiatric disorders 0.02 0.05 1.72 (0.41, 7.18) 0.457 
Renal and urinary disorders 0.42 0.40 1.04 (0.69, 1.55) 0.861 
Reproductive system and breast disorders 0.26 0.23 0.93 (0.56, 1.55) 0.779 
Respiratory, thoracic and mediastinal disorders 0.54 0.41 0.81 (0.56, 1.18) 0.281 
Skin and subcutaneous tissue disorders 0.04 0.09 2.05 (0.70, 5.99) 0.188 
Social circumstances 0.02 0.02 0.51 (0.08, 3.09) 0.464 
Surgical and medical procedures 0.50 0.38 0.79 (0.54, 1.17) 0.235 
Vascular disorders 0.42 0.37 0.92 (0.61, 1.37) 0.669 
Uncoded  0.02 0.06 2.69 (0.67, 10.82) 0.162 
 
Rate per 100 patient years; hazard ratio from time-updated Cox PH model 
 
 
